Positive Study Results, Market Activity, Acquisition Proposal, Earnings Schedules, and Collaboration - Research Reports on Avanir, Jazz, Alere, Intuitive Surgical and GSK

NEW YORK, September 18, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Alere Inc. (NYSE: ALR), Intuitive Surgical, Inc. (NASDAQ: ISRG) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6582-100free.

--
Avanir Pharmaceuticals, Inc. Research Reports
On September 15, 2014, Avanir Pharmaceuticals, Inc. (Avanir) announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. The Company said that patients treated with AVP-923 were significantly less agitated as compared to patients treated with placebo. Cheering the positive study results, the Company's stock rallied 85.31% to end the trading session at $12.49. "With no FDA approved drugs for the treatment of agitation in Alzheimer's disease, we believe these results represent a breakthrough for patients," said Joao Siffert, MD, chief medical officer at Avanir. The Company will present data from this phase II study at the American Neurological Association's (ANA) 2014 Annual Meeting in Baltimore, Maryland on October 12-14, 2014. The full research reports on Avanir are available to download free of charge at:

http://www.analystsreview.com/Sep-18-2014/AVNR/report.pdf

--
Jazz Pharmaceuticals plc Research Reports
On September 15, 2014, the stock of Jazz Pharmaceuticals plc (Jazz) fell 5.35% to end the trading session at $160.35. During the session, shares in Jazz opened at $167.69, and traded within the range of $156.79 - $168.39. A total of 1.42 million shares changed hands during the session. Form 4 (Statement of Changes in Beneficial Ownership) filed by Jazz that same day showed that Director Seamus Mulligan sold 50,000 shares of the Company on September 11, 2014. As per the filing, the shares were sold at an average price of $175.00. The full research reports on Jazz are available to download free of charge at:

http://www.analystsreview.com/Sep-18-2014/JAZZ/report.pdf

--
Alere Inc. Research Reports
On September 15, 2014, Alere Inc. (Alere) confirmed that Gregg J. Powers, Chairman of the Board, has received a letter from a group of former executives, led by former CEO Ron Zwanziger, requesting one month of due diligence to secure financing for making a bona fide offer for the Company. In his letter dated September 15, 2014, Zwanziger offered to acquire Alere for $46 per share - a premium of 25.65% over the stock's previous closing price on September 12, 2014. Zwanziger said that the offer price could be further increased upon completion of the due diligence after a month, and requested Gregg to consider the offer as it will boost the shareholder value. In his response to Zwanziger's offer, Gregg stated, "While Alere is concentrating on executing its business strategy, the directors are mindful of their obligations to shareholders and would of course give appropriate consideration to any bona fide proposal that would maximize shareholder value." Alere's stock rallied 12.37% to close at $41.14. The full research reports on Alere are available to download free of charge at:

http://www.analystsreview.com/Sep-18-2014/ALR/report.pdf

--
Intuitive Surgical, Inc. Research Reports
On September 15, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) reported that it will hold its Q3 2014 earnings conference call on October 21, 2014 at 4:30 p.m. ET. On average, analysts polled by Bloomberg expect the Company's EPS (pre-exceptional) at $2.95 in Q3 2014. The full research reports on Intuitive Surgical are available to download free of charge at:

http://www.analystsreview.com/Sep-18-2014/ISRG/report.pdf

--
GlaxoSmithKline plc Research Reports
On September 9, 2014, GlaxoSmithKline plc (GSK) announced that as part of its Africa NCD Open Lab initiative, it is collaborating with the UK and South African Medical Research Councils, to support research into non-communicable diseases (NCDs) in Africa. Under the collaboration, GSK will provide £1 million, together with a commitment of internal R&D expertise, to support projects within South Africa. The UK MRC and South African Medical Research Council will provide £2.5 million and £1.5 million, respectively, for the South African research proposals. Besides, GSK said that it will also commit a further £4 million to support successful proposals for NCD research from selected countries elsewhere in sub-Saharan Africa. Commenting on the collaboration, Patrick Vallance, President of Pharmaceutical R&D at GSK, said, "The funding announced today is a great endorsement of GSK's open research philosophy, and signifies growing agreement among the scientific community that collaboration is key to defeating some of the world's biggest health problems." The full research reports on GSK are available to download free of charge at:

http://www.analystsreview.com/Sep-18-2014/GSK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED